LSA Global
FEBRUARY 6, 2023
The team needs to scale to meet new and future challenges and be able to support a strong, integrated, and collaborative matrix operating model. The post LSA Global Delivers Facilitative Leadership Workshop for Biotech Company appeared first on LSA Global. Learn more about getting aligned.
Michael McKinney
MARCH 12, 2024
If sophisticated investors are involved — as often happens in biotech — the plan is undoubtedly subjected to intensive due diligence. Some fail for a host of strategic or operational shortcomings addressed in any decent business school course. No question the biotech industry is experiencing significant growth.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Sweet Process
FEBRUARY 28, 2022
Ineffective communication ruins business operations as team members will hardly be on the same page. In charge of the operations at Vendata Biosciences, a biotech company, Dan Couto got a hold of the many moving pieces by cultivating a culture of effective communication among his team members.
LSA Global
OCTOBER 23, 2023
Redwood Shores, CA – LSA Global, the leading business consulting, coaching, and training firm that helps fast growth life science, technology, and service companies by powerfully aligning their culture and talent with strategy, today announced results for a Biotech Leadership Influence Workshop. Job Relevance 96.3%
Chief Executive
NOVEMBER 3, 2022
Line clearance is most commonly used in regulated industries, such as pharmaceuticals, biotech, and food and beverage manufacturing. Often, operators need the use of their hands and must take pictures with a wearable camera. However, advanced sensors that would truly transform industrial operations are still costly.
Chief Executive
OCTOBER 31, 2022
Overall, the larger the company (by annual revenues), the more likely it is to invest in automation to curb the impact of wage increases, particularly when it comes to back-office operations. Real estate, at 23 percent, showed no change from the year prior, but pharma/biotech, at 18 percent, is down from 23 percent in 2021.
Chief Executive
JUNE 7, 2022
We were a company without any history of commercial operations,” David Meline told the recent CFO Leadership Council’s 12th Annual CFO Leadership Conference in Boston. “We I joined the biotech field at Amgen, and I can’t think of an area where there’s more opportunity and innovation going on.”. • Partner with governments.
Expert insights. Personalized for you.
36 
Let's personalize your content